Two separate routes: Part D and the GLP-1 Bridge
Medicare Part D has long excluded drugs used only for weight loss. Since 2024, Part D plans may cover GLP-1s for other FDA-approved uses: Wegovy for cardiovascular risk reduction (March 2024 indication) and Zepbound for moderate-to-severe obstructive sleep apnea with obesity (December 2024 indication). Separately, CMS runs the Medicare GLP-1 Bridge, which sits outside the Part D benefit.
| Route | What it covers | What you pay | Who it is for |
|---|---|---|---|
| Part D, type 2 diabetes | Ozempic, Mounjaro, Trulicity and others, per plan formulary | Plan cost-sharing | Enrollees with type 2 diabetes |
| Part D, other approved uses | Wegovy for cardiovascular risk reduction; Zepbound for sleep apnea, per plan rules | Plan cost-sharing; prior authorization common | Enrollees who meet the label and plan criteria |
| Medicare GLP-1 Bridge | Foundayo, Wegovy and the Zepbound KwikPen only (not Zepbound vials or single-dose pens) | $50 copay, July 1, 2026 to December 31, 2027; does not count toward the Part D out-of-pocket total | Part D enrollees with a BMI of 35 or more, or 30 or more or 27 or more with listed conditions (see Medicare.gov) |
Who is not eligible for the Bridge?
People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge, according to Medicare.gov. Their Part D plan "might cover" a GLP-1 for those conditions instead. That means a Zepbound user with sleep apnea, for example, goes through the Part D plan, not the Bridge.
What about BALANCE?
CMS's BALANCE model page (modified September 29, 2026) includes an FAQ about "the BALANCE Model not launching in Medicare in 2027" and states that the Bridge runs through December 31, 2027.
Open Enrollment
Medicare Open Enrollment runs October 15 to December 7, 2026, with changes effective January 1, 2027. You do not need a particular Part D plan to use the Bridge, but you do need Part D or a Medicare Advantage plan with drug coverage. If you take a GLP-1 for diabetes or another covered use, check that the drug is on the new plan's formulary and what prior authorization it requires.
What a year costs on each route
| Route | Arithmetic | 12 months |
|---|---|---|
| Bridge copay (CMS) | 12 × $50 | $600 |
| Wegovy pen self-pay, NovoCare (read October 15, 2026) | 12 × $349 | $4,188 |
| Compounded tirzepatide, NexLife 12-month plan (as of November 6, 2026) | 12 × $115 | $1,380 |
Medicare does not pay for compounded drugs, so a compounded program is always cash pay for a Medicare member, and compounded tirzepatide and semaglutide are not FDA-approved. If you qualify for the Bridge, the $50 copay is far lower than any cash option in our price index.
How to check your coverage
- Call the member services number on your card and ask whether Wegovy, Zepbound, Ozempic or Mounjaro is on the formulary, at what tier, and with what prior authorization criteria.
- Ask your prescriber whether you meet the Bridge criteria on Medicare.gov.
- Write down the date, the representative's name and any reference number.
More on brand drugs: Zepbound, Wegovy; other carriers: insurance hub.
Frequently asked questions
Does Medicare cover Zepbound vials through the Bridge?
No. Medicare.gov says the GLP-1 Bridge covers Zepbound only as the KwikPen; Zepbound vials and single-dose pens are excluded. Foundayo and Wegovy are the other covered drugs. The copay is $50 from July 1, 2026 to December 31, 2027 for eligible Part D enrollees.
Can I use the Bridge if I have type 2 diabetes?
No. Medicare.gov says people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge. For type 2 diabetes, Part D plans commonly cover drugs such as Ozempic, Mounjaro and Trulicity under the plan's own cost-sharing and rules.
Does Medicare pay for compounded semaglutide or tirzepatide?
No. Compounded GLP-1s are not FDA-approved and are not covered by Medicare, so they are cash pay. In our price table, the lowest all-in monthly figure for compounded tirzepatide ranged from $69 to $299 across 24 programs on reads of October 15 and November 6, 2026.
Do I need to change plans during Open Enrollment to get the Bridge?
No particular plan is required, but you need Part D or a Medicare Advantage plan with drug coverage. Open Enrollment runs October 15 to December 7, 2026. If you take a GLP-1 under Part D for another condition, check the new plan's formulary and prior authorization rules before switching.
Is the BALANCE model replacing the Bridge in 2027?
CMS's BALANCE page, modified September 29, 2026, includes an FAQ about "the BALANCE Model not launching in Medicare in 2027" and says the Bridge runs through December 31, 2027. We will update this page if CMS changes either program.
Sources
- Medicare.gov: weight-loss drugs and the GLP-1 Bridge — read November 8, 2026
- CMS: Medicare GLP-1 Bridge — page modified July 13, 2026; read October 15, 2026
- CMS: BALANCE model — page modified September 29, 2026; read October 15, 2026
- Medicare.gov: joining a plan (Open Enrollment dates) — read October 15, 2026
- NovoCare: Wegovy self-pay — read October 15, 2026
Comparing programs? Check the all-in monthly price, the named pharmacy and the cancellation terms on the provider's own page before you pay.
Check NexLife's plans and state availability → See the price index